Research Article
An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy
Table 1
Baseline patient characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||
Values are presented as n (%) or mean ± standard deviation. aDemographic data missing for 1 patient in the placebo group. bDemographic data missing for 2 patients in the probiotic group. cAmmonia data missing for 1 patient in the placebo group. dAmmonia data missing for 1 patient in the probiotic group. BMI: body mass index. |